These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 35508373)

  • 1. Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT.
    Kvistad SAS; Burman J; Lehmann AK; Tolf A; Zjukovskaja C; Melve GK; Bø L; Torkildsen Ø
    J Neurol Neurosurg Psychiatry; 2022 Aug; 93(8):844-848. PubMed ID: 35508373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial.
    Brittain G; Petrie J; Duffy KEM; Glover R; Hullock K; Papaioannou D; Roldan E; Beecher C; Bursnall M; Ciccarelli O; Coles AJ; Cooper C; Giovannoni G; Gabriel I; Kazmi M; Kyriakou C; Nicholas R; Paling D; Peniket A; Scolding N; Silber E; de Silva T; Venneri A; Walters SJ; Young C; Muraro PA; Sharrack B; Snowden JA;
    BMJ Open; 2024 Feb; 14(2):e083582. PubMed ID: 38316583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis.
    Bose G; Rush C; Atkins HL; Freedman MS
    Mult Scler Relat Disord; 2021 Jul; 52():102945. PubMed ID: 33901969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits of aHSCT over alemtuzumab in patients with multiple sclerosis besides disability and relapses: Sustained improvement in cognition and quality of life.
    Braun B; Fischbach F; Richter J; Pfeffer LK; Fay H; Reinhardt S; Friese MA; Stellmann JP; Kröger NM; Heesen C; Häußler V
    Mult Scler Relat Disord; 2024 Feb; 82():105414. PubMed ID: 38176284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab.
    Boffa G; Lapucci C; Sbragia E; Varaldo R; Raiola AM; Currò D; Roccatagliata L; Capello E; Laroni A; Mikulska M; Gualandi F; Uccelli A; Angelucci E; Mancardi GL; Inglese M
    Eur J Neurol; 2020 Oct; 27(10):2047-2055. PubMed ID: 32418281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term results of autografting persons with multiple sclerosis are better in those not exposed to prior disease-modifying therapies.
    Sánchez-Bonilla D; Robles-Nasta M; Gallardo-Pérez MM; Hernández-Flores EJ; Montes-Robles M; Pastelín-Martínez ML; Garcés-Eisele SJ; Olivares-Gazca JC; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
    Mult Scler Relat Disord; 2023 Jul; 75():104744. PubMed ID: 37178580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis.
    Mariottini A; Nozzoli C; Carli I; Landi F; Gigli V; Repice AM; Ipponi A; Cecchi M; Boncompagni R; Saccardi R; Massacesi L
    Neurol Sci; 2024 Jul; 45(7):3379-3387. PubMed ID: 38277051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis.
    Alping P; Burman J; Lycke J; Frisell T; Piehl F
    Neurology; 2021 Mar; 96(11):e1574-e1584. PubMed ID: 33514645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients.
    Vaivade A; Wiberg A; Khoonsari PE; Carlsson H; Herman S; Al-Grety A; Freyhult E; Olsson-Strömberg U; Burman J; Kultima K
    Lipids Health Dis; 2023 Jul; 22(1):97. PubMed ID: 37420217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline.
    Bayas A; Berthele A; Blank N; Dreger P; Faissner S; Friese MA; Gerdes LA; Grauer OM; Häussler V; Heesen C; Janson D; Korporal-Kuhnke M; Kowarik M; Kröger N; Lünemann JD; Martin R; Meier U; Meuth S; Muraro P; Platten M; Schirmer L; Stürner KH; Stellmann JP; Scheid C; Bergh FT; Warnke C; Wildemann B; Ziemssen T
    Ther Adv Neurol Disord; 2023; 16():17562864231180730. PubMed ID: 37780055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis.
    Häußler V; Ufer F; Pöttgen J; Wolschke C; Friese MA; Kröger N; Heesen C; Stellmann JP
    Ann Clin Transl Neurol; 2021 Jun; 8(6):1269-1278. PubMed ID: 33949790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing-remitting multiple sclerosis: an observational study.
    Zhukovsky C; Sandgren S; Silfverberg T; Einarsdottir S; Tolf A; Landtblom AM; Novakova L; Axelsson M; Malmestrom C; Cherif H; Carlson K; Lycke J; Burman J
    J Neurol Neurosurg Psychiatry; 2021 Feb; 92(2):189-194. PubMed ID: 33106366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of autologous hematopoietic stem-cell transplantation following natalizumab discontinuation in aggressive multiple sclerosis.
    Mariottini A; Innocenti C; Forci B; Magnani E; Mechi C; Barilaro A; Nistri R; Fani A; Saccardi R; Massacesi L; Repice AM
    Eur J Neurol; 2019 Apr; 26(4):624-630. PubMed ID: 30414315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous haematopoietic stem cell transplantation versus low-dose immunosuppression in secondary-progressive multiple sclerosis.
    Mariottini A; Bulgarini G; Forci B; Innocenti C; Mealli F; Mattei A; Ceccarelli C; Repice AM; Barilaro A; Mechi C; Saccardi R; Massacesi L
    Eur J Neurol; 2022 Jun; 29(6):1708-1718. PubMed ID: 35146841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous hematopoietic stem cell transplantation of patients with aggressive relapsing-remitting multiple sclerosis: Danish nation-wide experience.
    Jespersen F; Petersen SL; Andersen P; Sellebjerg F; Magyari M; Sørensen PS; Blinkenberg M
    Mult Scler Relat Disord; 2023 Aug; 76():104829. PubMed ID: 37364374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study.
    Silfverberg T; Zjukovskaja C; Ljungman P; Nahimi A; Ahlstrand E; Dreimane A; Einarsdottir S; Fagius J; Iacobaeus E; Hägglund H; Lange N; Lenhoff S; Lycke J; Mellergård J; Piehl F; Svenningsson A; Tolf A; Cherif H; Carlson K; Burman J
    J Neurol Neurosurg Psychiatry; 2024 Jan; 95(2):125-133. PubMed ID: 37748927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Healthcare utilization and costs associated with autologous haematopoietic stem cell transplantation in Norwegian patients with relapsing remitting multiple sclerosis.
    Gottschlich KN; Zolic-Karlsson Z; Aas E; Kvistad SAS; Bø L; Torkildsen Ø; Lehmann AK
    Mult Scler Relat Disord; 2024 Apr; 84():105507. PubMed ID: 38412758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
    Śladowska K; Kawalec P; Holko P; Osiecka O
    Neurol Sci; 2022 Sep; 43(9):5479-5500. PubMed ID: 35713731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with 'aggressive' multiple sclerosis.
    Das J; Snowden JA; Burman J; Freedman MS; Atkins H; Bowman M; Burt RK; Saccardi R; Innocenti C; Mistry S; Laud PJ; Jessop H; Sharrack B
    Mult Scler; 2021 Jul; 27(8):1198-1204. PubMed ID: 33565902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensive immunosuppression followed by autologous hematopoietic stem cell transplantation for the treatment of multiple sclerosis.
    Lycke J; Lenhoff S
    Ther Adv Neurol Disord; 2020; 13():1756286420929467. PubMed ID: 32636931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.